The Wnt signaling pathway effector TCF7L2 controls gut and brain proglucagon gene expression and glucose homeostasis
The FDA has approved specific GLP-1 medications for type 2 diabetes management and, in higher doses, certain agents (semaglutide 2.4 mg, liraglutide 3 mg, tirzepatide) for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
The participants were all classified as either overweight or having obesity, with an average baseline weight of 248.5 pounds
Cardiovascular outcomes Semaglutide has a major advantage here, not because its cardiovascular effects are necessarily superior, but because they have actually been measured in a dedicated outcomes trial
That dynamic is exactly why a monthly pen matters strategically
Starting at the full dose can cause severe nausea, vomiting, and other gastrointestinal effects that may force you to stop again